Marketing Manager - Hematology
About the job
- A bachelor's degree or above is required.
- More than six years of experience in pharmaceutical industry sales and marketing, including at least two years of marketing experience.
- Good customer insights, including understanding customer needs, behaviors, and motivational drivers.
- Product and industry/environment knowledge.
- Excellent analytical capability.
- Capability in strategic thinking and planning.
- Ability to engage and influence internal and external stakeholders to change perceptions or obtain commitment.
- Monitor, analyze, and evaluate market trends, consumer behaviors, and competitor activities to identify product market opportunities.
- Develop and implement national promotional campaigns, materials, and educational initiatives aligned with brand strategies.
- Work with the sales team and provide clear market direction and guidelines.
- Develop critical relationships with key opinion leaders and other allied health care professionals.
- Set up key opinion leader communication workshops to understand patient and physician insights.
- Collaborate with cross-functional teams to develop, integrate, and implement the operational plan and ensure alignment with brand strategy.
- Provide product knowledge to internal and external stakeholders.
- Develop and monitor budgets and forecasts.
- A medical or related major is preferred.
About the company
BeOne Medicines develops and commercializes cancer therapies for patients worldwide, focusing on hematologic cancers and solid tumors. Its products, including Brukinsa, are sold globally and supported by licensing partnerships, with internal R&D and clinical development driving a broad late-stage pipeline. BeOne differentiates itself by leveraging a large-scale clinical trial network and cost-efficient global drug development to achieve high margins while pursuing large-market indications. The company aims to expand into immunology and solid tumors while maintaining strong investment in R&D to make high-impact, accessible oncology treatments available in more than 45 countries.
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Dongcheng District, China
Founded
2010
Get referred to BeOne
See people who can refer or advise you
Simplify's Take
What believers are saying
- August 25, 2026 FDA approval expanded TEVIMBRA in first-line HER2-positive gastroesophageal cancer.
- August 31, 2026 Phase 3 survival data strengthened ZIIHERA-containing regimens.
- Q2 2026 revenue hit $1.7 billion; management raised 2026 guidance to $6.8 billion.
What critics are saying
- BeOne accepted developed-market pricing parity and Medicaid rebates on future U.S. approvals.
- Zydus' BRUKINSA ANDA lawsuit targets patents; a 2034 composition patent remains the fortress.
- AbbVie's trade-secrets case over BGB-16673 still threatens the BTK-degrader franchise.
What makes BeOne unique
- BeOne built 35-plus assets and 93 trials across 1,100 U.S. sites by September 2026.
- BRUKINSA dominates revenue, with 2026 global sales above $1.2 billion quarterly.
- Hopewell, New Jersey gives BeOne U.S. manufacturing, R&D, and packaging capacity.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
401(k) Retirement Plan
Wellness Program
Paid Vacation
Growth & Insights and Company News
6 month growth
8%1 year growth
-6%2 year growth
-1%Onco360, an independent specialty pharmacy, has been selected as a pharmacy partner by BeOne Medicines for Beqalzi (sonrotoclax). The drug is indicated for treating adults with relapsed or refractory mantle cell lymphoma after at least two lines of systemic therapy, including a Bruton's tyrosine kinase inhibitor. Beqalzi is a BCL-2 protein inhibitor. In a Phase 1/2 study of 103 adult patients with relapsed/refractory mantle cell lymphoma, the drug achieved an overall response rate of 52.4%, with a median time to response of 1.9 months. The median duration of response was 15.8 months. Onco360 is headquartered in Louisville, Kentucky, and operates as a flagship brand of PharMerica Corporation.
BeOne Medicines secured an exemption from Section 232 pharmaceutical tariffs through a voluntary agreement with the US government. The deal recognises over $1 billion in US manufacturing investment, including a $300 million expansion in Hopewell, New Jersey. The exemption protects BeOne from import duties on patented pharmaceuticals and ingredients. However, the company committed to pricing future FDA-approved medicines in line with other developed markets and participating in the Medicaid GENEROUS Model, which uses supplemental rebates. The Hopewell expansion will add small-molecule manufacturing and packaging capacity, creating approximately 120 full-time jobs. The facility will support a portfolio of more than 35 assets. Whilst the tariff exemption reduces supply-chain risk, international reference pricing commitments could limit pricing flexibility for future oncology medicines. Neither the tariff savings nor the financial impact of pricing concessions was disclosed.
Revolution Medicines has partnered with BeOne Medicines in a multi-part collaboration combining BeOne's oncology assets with Revolution's four clinical RAS(ON) inhibitors. The August 2026 deal grants BeOne exclusive development and commercialisation rights in select Asian markets and commits BeOne to fund a global Phase 3 trial. Revolution Medicines reported a net loss of $644.37 million in Q2 2026 and $1.1 billion over six months. The company currently generates no revenue but projects $2.3 billion in revenue and $402.5 million in earnings by 2029. The partnership shifts near-term risk by offloading Phase 3 costs whilst providing access to milestone and royalty potential. However, the core investment case remains unchanged: regulatory progress and commercialisation of daraxonrasib, with trial execution and spending presenting the biggest risks.
BeOne Medicines reported second-quarter revenue of $1.7 billion, up 30% year over year, with GAAP earnings per ADS rising 144% to $2.05. The company's BTK inhibitor BRUKINSA generated more than $1.2 billion in global sales, increasing 31% from the prior year. The company raised its 2026 revenue guidance to CNY 6.6 billion–CNY 6.8 billion and expects GAAP operating income of CNY 1 billion–CNY 1.1 billion. Free cash flow doubled year over year to CNY 435 million. BeOne received FDA approval for Beqalzi in relapsed or refractory mantle cell lymphoma and reported positive Phase III results for a chemotherapy-free BRUKINSA regimen. US BRUKINSA sales totalled $893 million, up 31%, driven by demand in chronic lymphocytic leukaemia and non-CLL indications.
John Oyler, chief executive officer of BeOne Medicines AG, sold 109,713 American Depositary Shares worth $34.6 million on 20 and 21 July 2026, according to SEC filings. The transactions were executed under a Rule 10b5-1 trading plan adopted in March 2026. Despite the sale, Oyler retains a substantial ownership position exceeding 50.4 million total shares through various holdings. These include 28.2 million shares held through Oyler Investment LLC and 9.5 million shares in a Roth IRA account. The shares were sold at a weighted average price of $315.28. BeOne Medicines is a commercial-stage oncology biopharmaceutical company with $5.7 billion in trailing twelve-month revenue and a market capitalisation of $34.2 billion.